This was the stock's second consecutive day of losses.
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback